Literature DB >> 30950440

Second primary malignancies in laryngeal carcinoma patients treated with definitive radiotherapy.

Yurday Ozdemir1, Erkan Topkan1.   

Abstract

INTRODUCTION: Second primary malignancy (SPM) is associated with decreased overall survival (OS) in laryngeal carcinomas (LC).
METHODS: One hundred eighty three LC patients were analyzed retrospectively. The primary and secondary endpoints were the incidence of SPM and the OS difference between patients with and without SPM.
RESULTS: SPM developed in 22 (12.0%) patients at median 52 months (range, 4-131 months), with a yearly 2.8% incidence, of which 19 (10.4%) and 3 (1.6%) were metachronous and synchronous, respectively. Lung was the commonest SPM (72.7%). Of 47 deaths, 12 (25.5%) were SPM related. Comparatively SPM patients had significantly shorter median OS (68.0 months vs. median not reached; P = 0.005), with lower 5-year (67.0% vs. 78.9%) and 8-year (32.6 vs. 69.8%) survival rates.
CONCLUSION: The present findings suggested the SPM as a competing risk factor for death in index LC patients with its annual incidence rate of 2.8% and for accounting one of every four deaths in this patients group. Emergence of lung carcinoma as the most frequent type of SPM and the ability to treat >50% of them with an estimated long-term outcomes emphasizes the importance of early diagnosis and curative treatment of SPMs.

Entities:  

Keywords:  Incidence; laryngeal carcinoma; lung carcinoma; overall survival; second primary malignancy

Mesh:

Year:  2019        PMID: 30950440     DOI: 10.4103/ijc.IJC_273_18

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  1 in total

1.  Erchen Plus Huiyanzhuyu Decoction Inhibits the Growth of Laryngeal Carcinoma in a Mouse Model of Phlegm-Coagulation-Blood-Stasis Syndrome via the STAT3/Cyclin D1 Pathway.

Authors:  Xi Tan; Qiulan Luo; Shiqing Zhou; Wei Huang; Xiaocong Feng; Wenyong Chen; Chaojie Yang; Yunying Li
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-22       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.